MedPath

Dietary energy density and type 2 diabetes

Phase 2
Conditions
diabetes.
????? ??? 2 ? ???? ?????????? ??????? ??? ?????? ??????? ??? 2
Registration Number
IRCT201105281485N4
Lead Sponsor
Vice chancellor for research,Isfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
60
Inclusion Criteria

Diabetic non-pregnant and non-lactating females aged 30-60 y, Lack of insulin injection, non-smokers, lack of having a special diet except for usual diabetes meal plan, lack of sever weight loss in the last 3 months, not having sever infection in the last 3 months, trauma, surgery, hypo- and hyper-thyroidism, lack of the use of vasodialators, antioxidant supplements, vitamin and mineral supplements, diuretics, betablockers, garlet, OCP, aspirine and corticosteroids.

Exclusion criteria: Lack of adherence to the prescribed diet, starting the use of above-mentioned medications or affecting by the above-mentioned diseases, alterations in dosage and type of current medications, getting pregnant

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum visfatin level. Timepoint: before the intervention week 8. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA) ?ng/dL.;Serum adiponectin level. Timepoint: before the intervention week 8. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA) ?ug/dL.;Serum chemerin level. Timepoint: before the intervention week 8. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA) ?ng/dL.;Serum high sensitive Interleukin 6 (hs IL-6) levels. Timepoint: before intervention and week 8. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA) ?ng/dL.;Serum high sensitive tumor necrosis factor-alpha (hs TNF-a) levels. Timepoint: before intervention and week 8. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA) ?mg/dL.;Serum high sensitive-C Reactive Protein (hs-CRP) levels. Timepoint: before the intervention week 8. Method of measurement: high sensitive immunoturbidimetry, mg/dL.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath